THE IMPORTANCE OF INTRAVENOUS IMMUNOGLOBULINS IN THETREATMENT OF ADULT HEMATOLOGICAL DISEASES
Abstract
BACKGROUND Intravenous immunoglobulins (IVIG) are preparations made from human plasma andcontain beside immunoglobulin G a wide spectrum of other endemic antibodies againstinfectious diseases typical for Slovenia. The purpose of treatment with IVIG is to restorenormal immunoregulatory mechanisms in human body. The use of IVIG is different: asreplacement therapy in primary and secondary immunodefficiency (lack of antibodies,impossibility of producing antibodies), as prophylactic treatment of some infections (cytomegalovirus, parvovirus B19) and for treatment of autoimmune diseases as idiopathicthrombocytopenic purpura. CONCLUSIONS As showed with pharmacokinetics study in patients with chronic lymphocytic leukemiaand multiple myeloma, IVIG has no influence on normal distribution of IgG and otherantibodies. In the paper there are shown multiple possible mechanisms of IVIG action,although they haven’t been understood yet. There is a big possibility that some otherantibodies, which are present in the IVIG, are involved. The relative good effect of IVIGtreatment in different hematological diseases became of interest for prevention and treatment of some neurologic and neuromuscular diseasesDownloads
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
